Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer

  • Maryam Soleimani Dodaran (Contributor)
  • Simone Borgoni (Contributor)
  • Emre Sofyall (Contributor)
  • Pernette J. Verschure (Contributor)
  • Stefan Wiemann (Contributor)
  • Perry D Moerland (Contributor)
  • Antoine van Kampen (Contributor)

    Dataset

    Description

    Background Estrogen receptor (ER) positive breast cancer is often effectively treated with drugs that inhibit ER signaling, i.e., tamoxifen (TAM) and aromatase inhibitors (AIs). However, 30% of ER+ breast cancer patients develop resistance to therapy le...
    Date made available2020
    PublisherSpringer Nature

    Access Dataset

    Cite this